NHS England has suspended the prescribing of gender-affirming cross-sex hormones to individuals under 18 years of age, citing insufficient evidentiary support for the intervention. The decision, announced in early 2026, initiates a 90-day public consultation period during which NHS England will consider permanently removing these treatments from the standard care pathway for minors presenting with gender incongruence or gender dysphoria.

The suspension applies to oestrogen and testosterone prescriptions issued within the context of gender-affirming care for patients aged 16 and 17. Prior to the pause, NHS England permitted the prescribing of these hormones to adolescents in this age range who carried a formal diagnosis of gender incongruence or gender dysphoria and who met a defined set of clinical criteria, typically in conjunction with psychological support services. Patients currently receiving masculinising or feminising hormones through the NHS will not face immediate cessation of treatment, but NHS England has directed that each such case undergo individual clinical review.

The policy shift follows an evidence review commissioned by NHS England, the findings of which indicated that the available data did not substantiate routine clinical use of cross-sex hormones in this population. The review examined the strength of evidence underpinning the use of these pharmacological interventions in adolescents, with particular attention to long-term safety data, psychological outcomes, and the persistence of gender dysphoria into adulthood. NHS England concluded that the evidence base was insufficient to support continued routine prescribing.

Clinical Context and Pharmacological Considerations

Cross-sex hormone therapy in adolescents involves the administration of oestrogen to individuals assigned male at birth, or testosterone to individuals assigned female at birth, with the goal of inducing secondary sex characteristics concordant with the patient’s gender identity. These agents produce physiological changes that include alterations in fat distribution, muscle mass, bone density, and, in many cases, fertility. A clinically notable concern is that several of these changes are irreversible upon cessation of treatment. The irreversibility of certain effects, including effects on fertility and physical development, has been central to the ongoing debate regarding the appropriate age threshold and evidentiary standard for initiating such treatment.

Cross-sex hormones differ from gonadotropin-releasing hormone (GnRH) analogues, which suppress pubertal development and were the subject of an earlier NHS restriction. GnRH analogues were restricted to research settings by NHS England following publication of the Cass Review, an independent review led by paediatrician Dr. Hilary Cass and published in April 2024. The Cass Review concluded that the evidence for puberty suppression in children and adolescents with gender dysphoria was of low certainty, a finding that informed subsequent policy decisions across the NHS. The current pause on cross-sex hormones represents an extension of that evidentiary scrutiny to the next step in the standard gender-affirming care pathway.

Evidentiary Standards and the Cass Review

The Cass Review examined a substantial volume of published literature on the clinical management of gender dysphoria in children and adolescents. Its central finding was that the evidence base was characterised by studies of low methodological quality, small sample sizes, short follow-up durations, and inadequate control populations. The review identified particular gaps in data on long-term psychological outcomes, rates of desistance and persistence of gender dysphoria across developmental stages, and the comparative efficacy of psychosocial versus pharmacological interventions. These findings informed NHS England’s decision to restrict GnRH analogue prescribing and now appear to have directly influenced the current suspension of cross-sex hormone treatment for minors.

The absence of robust randomised controlled trial (RCT) data has long been acknowledged by clinicians practicing in this field. Conducting double-blind RCTs in this population presents both ethical and practical challenges, a constraint that is not unique to gender medicine but one that carries particular weight when the interventions under scrutiny produce irreversible effects. NHS England’s position reflects a determination that, in the absence of high-quality evidence, the precautionary principle warrants a pause in routine prescribing rather than continuation under conditions of clinical uncertainty.

Systematic reviews assessing outcomes such as psychological wellbeing, suicidality, quality of life, and gender dysphoria severity following cross-sex hormone treatment in adolescents have generally reported methodological limitations that preclude definitive conclusions. Studies that have demonstrated improvements in psychological outcomes have frequently been criticised for the absence of control groups, high dropout rates, and short follow-up periods that do not capture outcomes beyond early adulthood. NHS England’s evidence review appears to have applied a standard consistent with these acknowledged limitations.

Reactions from Advocacy Groups and the Medical Community

Trans advocacy organisations responded to the announcement with marked criticism. Several groups characterised the suspension as harmful to a medically vulnerable population, with at least one organisation describing the decision as cruel. Advocacy bodies have argued that withholding access to gender-affirming hormones during adolescence may have adverse psychological consequences, and some have indicated that legal challenges are under consideration.

The medical community has not responded with a unified position. Professional bodies and individual clinicians have expressed divergent views that reflect broader disagreements within the field regarding the appropriate clinical threshold for initiating hormonal intervention in minors, the weight that should be assigned to available evidence, and the long-term consequences of both treatment and treatment deferral. Some clinicians have expressed support for the NHS position, arguing that the evidentiary bar for irreversible interventions in minors should be higher than what current literature supports. Others have argued that the evidence, while imperfect, is sufficient to justify treatment in carefully selected cases, and that restricting access to hormones will not eliminate the underlying clinical need but will instead redirect some patients toward private providers or unregulated sources.

Regulatory Trajectory in England

The current pause sits within a broader regulatory trajectory in England that has moved progressively toward restriction of gender-affirming medical interventions for minors. The closure of the Gender Identity Development Service (GIDS) at the Tavistock and Portman NHS Foundation Trust in 2023 and its replacement by a network of regional gender clinics for young people represented a structural reorganisation driven by concerns about clinical governance and patient safety. The Cass Review’s recommendations, which called for a more cautious, evidence-based approach and greater investment in research, provided a clinical rationale for both the reorganisation and the subsequent prescribing restrictions.

The 90-day public consultation announced alongside the pause will determine whether cross-sex hormone treatment is permanently removed from NHS provision as a routine intervention for under-18s. The consultation is expected to receive submissions from clinicians, researchers, patient groups, legal bodies, and the general public. NHS England has indicated that individual patients currently receiving hormones will continue to have access during the consultation period, subject to clinical review, which provides some continuity of care for an estimated cohort of adolescents whose treatment predates the suspension.

Relevance to Pacific and Asia-Pacific Clinical Practice

The NHS decision carries relevance beyond England. Regulatory determinations made by major national health systems carry influence over clinical guideline development in other jurisdictions, including Hawaii and the broader Pacific region. The Hawaii Department of Health and clinical institutions serving Native Hawaiian, Pacific Islander, and Asian-American populations have navigated the management of gender dysphoria in adolescents within a healthcare context shaped by both continental U.S. policy and the specific cultural dynamics of the Pacific.

Pacific Islander adolescents with gender incongruence represent a population with distinct cultural frameworks, including the recognised social role of the Mahu in Native Hawaiian tradition, that intersect with Western clinical categories in ways that complicate direct application of evidence generated in European or continental U.S. cohorts. Subgroup-level outcome data for Pacific Islander and Native Hawaiian patients within gender medicine research remain sparse, a gap that limits the extent to which clinical decisions for these populations can be grounded in population-specific evidence. The absence of such data reinforces the importance of conducting research that captures outcomes in demographically and culturally distinct cohorts, rather than relying exclusively on generalisation from majority-population studies.

Outstanding Clinical Questions

The NHS pause does not resolve the underlying clinical questions that have driven debate in this field. The central question, whether the psychological benefits of gender-affirming hormone treatment in carefully selected adolescents outweigh the risks associated with irreversible physiological change and long-term pharmacological exposure, remains without a definitive answer supported by high-quality evidence. NHS England has determined that the current evidentiary standard does not justify routine prescribing; it has not determined that harm definitively outweighs benefit in all cases, a distinction that will be relevant to how the public consultation proceeds and how individual clinical teams manage patients currently under review.

The 90-day consultation period will represent an opportunity for the research community to present a consolidated assessment of available evidence, including data that may not have been incorporated into the NHS review. The outcome of that consultation and any subsequent formal guidance changes will be monitored closely by clinicians, researchers, and policymakers in jurisdictions that have not yet reached comparable regulatory determinations.